Programmed Death Receptor-1 Blocking Antibody [EPC]

114888 reported adverse events

Drugs of this class: ATEZOLIZUMAB DOSTARLIMAB NIVOLUMAB NIVOLUMAB AND RELATLIMAB-RMBW PEMBROLIZUMAB

These side effects are most commonly reported by patients taking drugs of the Programmed Death Receptor-1 Blocking Antibody [EPC] class:

# Side effect Count
0 MALIGNANT NEOPLASM PROGRESSION 13025
1 DEATH 12556
2 DIARRHOEA 5449
3 OFF LABEL USE 4979
4 FATIGUE 4960
5 PYREXIA 4805
6 DYSPNOEA 3574
7 NAUSEA 3525
8 RASH 3409
9 PRODUCT USE IN UNAPPROVED INDICATION 3248
See all common reactions for Programmed Death Receptor-1 Blocking Antibody [EPC]

Drugs of the Programmed Death Receptor-1 Blocking Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 IMMUNE-MEDIATED HYPERTHYROIDISM 35 1.0000
1 IMMUNE-MEDIATED HYPOTHYROIDISM 133 0.9638
2 IMMUNE-MEDIATED THYROIDITIS 81 0.9529
3 IMMUNE-MEDIATED CHOLANGITIS 55 0.9483
4 IMMUNE-MEDIATED DERMATITIS 101 0.9439
5 IMMUNE-MEDIATED HEPATIC DISORDER 313 0.9428
6 IMMUNE-MEDIATED MYOCARDITIS 230 0.9350
7 IMMUNE-MEDIATED PANCREATITIS 79 0.9186
8 IMMUNE-MEDIATED HYPOPHYSITIS 44 0.8980
9 IMMUNE-MEDIATED ENCEPHALITIS 83 0.8830
See all enriched reactions for Programmed Death Receptor-1 Blocking Antibody [EPC]